HC Wainwright Has Positive Outlook for DBVT FY2026 Earnings

DBV Technologies S.A. (NASDAQ:DBVT) – Investment analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for DBV Technologies in a report issued on Monday, May 5th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.85) for the year, up from their prior forecast of ($5.55). HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for DBV Technologies’ current full-year earnings is ($7.05) per share. HC Wainwright also issued estimates for DBV Technologies’ FY2027 earnings at ($0.78) EPS and FY2028 earnings at ($0.37) EPS.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Friday, April 11th. The company reported ($1.10) earnings per share (EPS) for the quarter. The firm had revenue of $0.51 million for the quarter. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%.

DBVT has been the topic of several other research reports. JMP Securities upped their target price on shares of DBV Technologies from $10.00 to $15.00 and gave the stock a “market outperform” rating in a report on Thursday, May 1st. StockNews.com upgraded DBV Technologies from a “sell” rating to a “hold” rating in a report on Friday.

DBV Technologies Price Performance

Shares of DBV Technologies stock opened at $9.95 on Wednesday. The company’s fifty day moving average price is $6.80 and its two-hundred day moving average price is $4.82. The firm has a market capitalization of $272.39 million, a PE ratio of -2.21 and a beta of -0.66. DBV Technologies has a 52-week low of $2.20 and a 52-week high of $10.12.

Hedge Funds Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies at the end of the most recent reporting period. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.